Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446499 | 0.89 | PDE4B (0.48) | PDE4BPI4KBROCK2ROCK1TSHR | |
| SCHEMBL19118055 | 0.87 | PDE4B (0.44) | PDE4BPI4KBROCK2ROCK1ALDH1A1 | |
| SCHEMBL17784223 | 0.83 | PDE4B (0.54) | PDE4BPI4KBROCK2ROCK1TSHR | |
| SCHEMBL17784225 | 0.74 | PDE4B (0.64) | PDE4BROCK2ROCK1TSHRMEN1 | |
| SCHEMBL19118056 | 0.73 | PDE4B (0.60) | PDE4BROCK2ROCK1TSHRMAPT | |
| SCHEMBL17784206 | 0.72 | PDE4B (0.79) | PDE4BPI4KBROCK2ROCK1TSHR | |
| SCHEMBL16446545 | 0.72 | PDE4B (0.36) | PDE4BROCK2ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL17784211 | 0.72 | PDE4B (0.79) | PDE4BPI4KBROCK2ROCK1LMNA | |
| SCHEMBL17784228 | 0.72 | PDE4B (0.79) | PDE4BROCK2ROCK1TSHR | |
| SCHEMBL16446841 | 0.68 | PDE4B (0.67) | PDE4BROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030565-B1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9688683-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-3030565-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2015018534-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | PDE4A, PDE4B, TYMP | PDE4B 2/4885PI4KB 521/4885FAAH 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.